Adagrasib (MRTX849) is a potent, selective, and covalent KRAS G12C inhibitor. It affects the KRAS/MAPK/ERK signaling pathways by covalently binding to the mutant KRAS protein at Cys12, effectively inhibiting KRAS-dependent signal transduction and suppressing cancer cell viability and proliferation.
Adagrasib (MRTX849) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Adagrasib (MRTX849) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.